| TrovaGene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach to develop targeted therapies for the treatment of patients with leukemias, lymphomas and solid tumor cancers. Co.'s drug candidate, onvansertib, is an oral and highly-selective Polo-like Kinase 1 (PLK1) adenosine triphosphate competitive inhibitor. PLK1 is essential for regulating the cell division and maintaining genome stability in mitosis (cell division), spindle assembly, and DNA damage response. Co.'s intellectual property and proprietary technology enables it to analyze circulating tumor DNA and clinically actionable markers for predicting response to cancer therapies. We show 9 historical shares outstanding datapoints in our TROV shares outstanding history coverage, used to compute TROV market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TROV market cap history over the course of time is important for investors
interested in comparing TROV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TROV versus a peer is one thing; comparing
TROV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TROV can fluctuate over the course of history.
With this page we aim to empower investors researching TROV by allowing them to research the TROV market cap history.